drugset / Trial / NCT01114841

A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers

NCT01114841

Phase 1 Completed 254 enrolled Stiefel, a GSK Company GlaxoSmithKline · collab
RandomizedParallel-groupSingle-blindBasic science

Summary

This study will assess the potential of tazarotene foam to cause sensitization during a 48 hour challenge following 21 days of exposure on the skin of healthy volunteers.

Timeline

Start
2010-03-31
Primary completion
2010-06-26
Completion
2010-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazarotene Small molecule 0.1 % Topical

Indications